Diagnostic Tests for Kidney Cancer

Urologists provide an overview of diagnostic tests for patients with kidney cancer, highlighting lab tests, imaging, and considerations for biopsy.

EP: 1.A Growing Incidence of Renal Masses

Now Viewing

EP: 2.Diagnostic Tests for Kidney Cancer

EP: 3.Limitations of Conventional Imaging for Assessing Renal Masses

EP: 4.The Role of a Multidisciplinary Team in Managing Kidney Cancer

EP: 5.Staging and Treatment Decisions for Kidney Cancer

EP: 6.Advances in Imaging for Kidney Cancer Diagnosis and Management

EP: 7.Overview of Clinical Trials for New Imaging Options for Kidney Cancer

EP: 8.Potential Impact of PET/CT Imaging on Improving Patient Care

Related Videos

Related Content

Advertisement

August 1st 2025

Metastasis-directed radiotherapy without systemic therapy yields promising outcomes in oligometastatic ccRCC

Hannah Clarke

MRWS was shown to prolong the time off systemic therapy and was associated with favorable tolerability.

August 1st 2025

Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD

Amy M. Pearlman, MD

Bansal unpacks how to personalize treatment plans in a therapeutic landscape now filled with minimally invasive and surgical options.

August 1st 2025

What urologists can expect in Q3 of 2025

Benjamin P. Saylor Hannah Clarke

A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.

August 1st 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

August 1st 2025

Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma

Hannah Clarke

The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.

August 1st 2025

Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

Benjamin P. Saylor

ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.

Related Content

Advertisement

August 1st 2025

Metastasis-directed radiotherapy without systemic therapy yields promising outcomes in oligometastatic ccRCC

Hannah Clarke

MRWS was shown to prolong the time off systemic therapy and was associated with favorable tolerability.

August 1st 2025

Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD

Amy M. Pearlman, MD

Bansal unpacks how to personalize treatment plans in a therapeutic landscape now filled with minimally invasive and surgical options.

August 1st 2025

What urologists can expect in Q3 of 2025

Benjamin P. Saylor Hannah Clarke

A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.

August 1st 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

August 1st 2025

Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma

Hannah Clarke

The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.

August 1st 2025

Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

Benjamin P. Saylor

ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.